Cardio Diagnostics, Inc, a biotechnology company making cardiovascular disease prevention and early detection more accessible, personalized and precise, announces the launch of its patent-pending ...
CHICAGO--(BUSINESS WIRE)--Cardio Diagnostics Holdings, Inc. (Nasdaq: CDIO), a leader in artificial intelligence-driven precision cardiovascular medicine tests, and Family Medicine Specialists (FMS), a ...
Cardio Diagnostics CDIO, a leader in artificial intelligence-driven precision cardiovascular medicine, has published a potentially revolutionary study in the Journal of the American Heart Association ...
Cardio Diagnostics Holdings Inc. (NASDAQ:CDIO), an AI-powered precision cardiovascular medicine company, is making progress in gaining broad access to Medicare reimbursement for its Epi+Gen CHD™ and ...
Obtaining the payment rates marks a key milestone in gaining broad access to Medicare reimbursement. CHICAGO, July 22, 2025--(BUSINESS WIRE)--Cardio Diagnostics Holdings, Inc. (Nasdaq: CDIO), an ...
Deepak L. Bhatt, MD, MPH: Let me turn now to Dr Navar to discuss what I think is an important part of the discussion. She’s done a lot of work on this. How do we actually estimate patients’ risk for ...
Some days, you need to see just how well your lungs are working for you. Obviously, if you take a run or swim test regularly, you'll be on top of things, but sometimes you still can test in other ...
A genetic risk for heart disease is far less predictive of problems than actual lifestyle risk factors such as high blood pressure, high cholesterol and diabetes -- even among younger adults. In a ...
The final gapfill payment rate for both the Epi+Gen CHD™ and PrecisionCHD™ tests is higher at $854 compared to the preliminary gapfill payment rates of $350 for Epi+Gen CHD™ and $684.76 for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback